Tong Ren Tang Technologies Inkomsten in het verleden
Verleden criteriumcontroles 2/6
Tong Ren Tang Technologies has been growing earnings at an average annual rate of 7.9%, while the Pharmaceuticals industry saw earnings growing at 5.7% annually. Revenues have been growing at an average rate of 10.7% per year. Tong Ren Tang Technologies's return on equity is 10.3%, and it has net margins of 9.5%.
Belangrijke informatie
7.9%
Groei van de winst
7.9%
Groei van de winst per aandeel
Pharmaceuticals Groei van de industrie | 5.6% |
Inkomstengroei | 10.7% |
Rendement op eigen vermogen | 10.3% |
Nettomarge | 9.5% |
Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
There's Reason For Concern Over Tong Ren Tang Technologies Co. Ltd.'s (HKG:1666) Massive 34% Price Jump
Oct 07Is Tong Ren Tang Technologies (HKG:1666) Using Too Much Debt?
Sep 28We Think You Should Be Aware Of Some Concerning Factors In Tong Ren Tang Technologies' (HKG:1666) Earnings
Sep 06Investor Optimism Abounds Tong Ren Tang Technologies Co. Ltd. (HKG:1666) But Growth Is Lacking
May 25Here's Why Tong Ren Tang Technologies (HKG:1666) Can Manage Its Debt Responsibly
Mar 28Subdued Growth No Barrier To Tong Ren Tang Technologies Co. Ltd.'s (HKG:1666) Price
Feb 01With EPS Growth And More, Tong Ren Tang Technologies (HKG:1666) Makes An Interesting Case
Dec 20Tong Ren Tang Technologies (HKG:1666) Could Easily Take On More Debt
Oct 12Is Tong Ren Tang Technologies Co. Ltd. (HKG:1666) Trading At A 38% Discount?
Sep 19Do Tong Ren Tang Technologies' (HKG:1666) Earnings Warrant Your Attention?
Apr 13Is Tong Ren Tang Technologies (HKG:1666) Using Too Much Debt?
Dec 01Here's Why Tong Ren Tang Technologies (HKG:1666) Can Manage Its Debt Responsibly
Aug 30Is Tong Ren Tang Technologies Co. Ltd. (HKG:1666) Trading At A 43% Discount?
Jul 11Tong Ren Tang Technologies (HKG:1666) Seems To Use Debt Rather Sparingly
Apr 21We Think Tong Ren Tang Technologies (HKG:1666) Can Manage Its Debt With Ease
Dec 22Tong Ren Tang Technologies (HKG:1666) Seems To Use Debt Rather Sparingly
Sep 06Is Tong Ren Tang Technologies (HKG:1666) Using Too Much Debt?
Apr 25Tong Ren Tang Technologies Co. Ltd.'s (HKG:1666) Intrinsic Value Is Potentially 22% Below Its Share Price
Mar 20Is Tong Ren Tang Technologies Co. Ltd. (HKG:1666) A Great Dividend Stock?
Feb 21Tong Ren Tang Technologies Co. Ltd.'s (HKG:1666) Has Performed Well But Fundamentals Look Varied: Is There A Clear Direction For The Stock?
Feb 03If You Had Bought Tong Ren Tang Technologies' (HKG:1666) Shares Three Years Ago You Would Be Down 61%
Jan 16What Can We Learn About Tong Ren Tang Technologies' (HKG:1666) CEO Compensation?
Dec 28Does This Valuation Of Tong Ren Tang Technologies Co. Ltd. (HKG:1666) Imply Investors Are Overpaying?
Dec 15What Kind Of Shareholders Hold The Majority In Tong Ren Tang Technologies Co. Ltd.'s (HKG:1666) Shares?
Dec 02Opbrengsten en kosten
Hoe Tong Ren Tang Technologies geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Jun 24 | 6,877 | 651 | 1,710 | 0 |
31 Mar 24 | 6,825 | 620 | 1,721 | 0 |
31 Dec 23 | 6,773 | 590 | 1,732 | 0 |
30 Sep 23 | 6,849 | 611 | 1,652 | 0 |
30 Jun 23 | 6,924 | 633 | 1,572 | 0 |
31 Mar 23 | 6,458 | 608 | 1,475 | 0 |
31 Dec 22 | 5,992 | 583 | 1,378 | 0 |
30 Sep 22 | 5,820 | 546 | 1,331 | 0 |
30 Jun 22 | 5,649 | 510 | 1,284 | 0 |
31 Mar 22 | 5,525 | 509 | 1,248 | 0 |
31 Dec 21 | 5,400 | 507 | 1,212 | 0 |
30 Sep 21 | 5,267 | 509 | 1,226 | 0 |
30 Jun 21 | 5,133 | 511 | 1,240 | 0 |
31 Mar 21 | 4,870 | 489 | 1,182 | 0 |
31 Dec 20 | 4,607 | 468 | 1,125 | 0 |
30 Sep 20 | 4,425 | 387 | 1,099 | 0 |
30 Jun 20 | 4,242 | 307 | 1,073 | 0 |
31 Mar 20 | 4,359 | 362 | 1,094 | 0 |
31 Dec 19 | 4,476 | 418 | 1,116 | 0 |
30 Sep 19 | 4,604 | 523 | 1,099 | 0 |
30 Jun 19 | 4,731 | 628 | 1,082 | 0 |
31 Mar 19 | 4,895 | 653 | 1,157 | 0 |
31 Dec 18 | 5,060 | 678 | 1,231 | 0 |
30 Sep 18 | 5,054 | 681 | 1,295 | 0 |
30 Jun 18 | 5,047 | 683 | 1,359 | 0 |
31 Mar 18 | 5,036 | 675 | 1,359 | 0 |
31 Dec 17 | 5,025 | 667 | 1,359 | 0 |
30 Sep 17 | 4,882 | 624 | 1,367 | 0 |
30 Jun 17 | 4,739 | 582 | 1,375 | 0 |
31 Mar 17 | 4,702 | 589 | 1,367 | 0 |
31 Dec 16 | 4,665 | 596 | 1,359 | 0 |
30 Sep 16 | 4,546 | 603 | 1,297 | 0 |
30 Jun 16 | 4,426 | 610 | 1,235 | 0 |
31 Mar 16 | 4,247 | 575 | 1,183 | 0 |
31 Dec 15 | 4,067 | 541 | 1,131 | 0 |
30 Sep 15 | 3,915 | 529 | 1,081 | 0 |
30 Jun 15 | 3,764 | 517 | 1,032 | 0 |
31 Mar 15 | 3,552 | 490 | 968 | 0 |
31 Dec 14 | 3,341 | 462 | 904 | 0 |
30 Sep 14 | 3,246 | 446 | 879 | 0 |
30 Jun 14 | 3,151 | 430 | 855 | 0 |
31 Mar 14 | 3,031 | 410 | 841 | 0 |
31 Dec 13 | 2,911 | 390 | 826 | 0 |
Kwaliteitswinsten: 1666 has a high level of non-cash earnings.
Groeiende winstmarge: 1666's current net profit margins (9.5%) are higher than last year (9.1%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 1666's earnings have grown by 7.9% per year over the past 5 years.
Versnelling van de groei: 1666's earnings growth over the past year (2.9%) is below its 5-year average (7.9% per year).
Winst versus industrie: 1666 earnings growth over the past year (2.9%) did not outperform the Pharmaceuticals industry 6.4%.
Rendement op eigen vermogen
Hoge ROE: 1666's Return on Equity (10.3%) is considered low.